UNITY Biotechnology Announces Positive 12-Week Data from Phase 1 Clinical Trial of UBX1325 in Advanced Vascular Eye Disease
05. Oktober 2021 07:00 ET
|
Unity Biotechnology, Inc.
Evidence of improvement in vision and retinal structure in patients with DME and AMD sustained through 12 weeks Sustained responses following single treatment with UBX1325 support durability of...
UNITY Biotechnology, Inc. to Participate in Upcoming Investor Conferences
07. September 2021 16:00 ET
|
Unity Biotechnology, Inc.
16th Annual Citi BioPharma Conference on September 8-10, 2021 Morgan Stanley 19th Annual Global Healthcare Conference on September 9-15, 2021 23rd H.C. Wainwright Global Investment Conference on...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
18. August 2021 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology, Inc. to Participate in the H.C. Wainwright Ophthalmology Virtual Conference
16. August 2021 16:03 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 16, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of...
UNITY Biotechnology, Inc. Reports Second Quarter 2021 Financial Results and Business Updates
10. August 2021 16:01 ET
|
Unity Biotechnology, Inc.
UBX1325 demonstrates favorable tolerability in Phase 1 safety study and improvement in visual acuity and central subfield thickness in majority of patients with diabetic macular edema (DME) and wet...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
28. Juli 2021 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology to Host Investor Call with Retinal Expert Robert Bhisitkul, M.D., Ph.D., to Discuss Recent Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
23. Juli 2021 08:00 ET
|
Unity Biotechnology, Inc.
UNITY management team and Dr. Bhisitkul to discuss initial safety and efficacy data supporting improvements in vision and structure seen in patients treated with a single dose of UBX1325 UNITY...
UNITY Biotechnology Announces Positive Data from Phase 1 Clinical Trial of UBX1325 in Patients with Advanced Vascular Eye Disease
06. Juli 2021 07:00 ET
|
Unity Biotechnology, Inc.
Improvement in Visual Acuity and Central Subfield Thickness observed in diabetic macular edema (DME) and wet age-related macular degeneration (wet AMD) patients treated with UBX1325 UBX1325...
UNITY Biotechnology Reports Granting of New Employment Inducement Awards
02. Juni 2021 08:00 ET
|
Unity Biotechnology, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases...
UNITY Biotechnology, Inc. Reports First Quarter 2021 Financial Results and Business Updates
11. Mai 2021 08:00 ET
|
Unity Biotechnology, Inc.
- UBX1325 demonstrates favorable tolerability in Phase 1 safety study with initial evidence of relevant biological activity - Phase 2a proof-of-concept study initiated in patients with diabetic...